SCM
COGT icon

Soleus Capital Management’s Cogent Biosciences COGT Stock Holding History

Soleus Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$385K – 100
2026
Q1 		$385K Sell
10,000
-110,000
-92% -$4.06M 0.02% 84
2025
Q4 		$4.26M Buy
+120,000
New +$3.37M 0.16% 71
2020
Q4 		– Sell
-11,975
Closed -$112K – 68
2020
Q3 		$112K Buy
+11,975
New +$125K 0.06% 63

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Soleus Capital Management's COGT Position: Q2 2026 in Review

Soleus Capital Management sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 10,000 shares — an estimated $385K sold.

Soleus Capital Management first reported a position in COGT in Q3 2020 and held it in 3 quarters. The position peaked at $4.26M in Q4 2025. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Soleus Capital Management reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
  • Soleus Capital Management sold 10,000 Cogent Biosciences shares in Q2 2026, an estimated $385K.
  • Soleus Capital Management first reported a position in Cogent Biosciences in Q3 2020 and held it in 3 quarters.
  • Soleus Capital Management's Cogent Biosciences position peaked at $4.26M in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.